SCHEMBL4602071

SCHEMBL4602071

Fc1ccc(CNc2nccs2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
HPGD P15428 5/20 0.51
NPC1 O15118 4/20 0.51
RAB9A P51151 4/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
TP53 P04637 1/20 0.51
ALOX15 P16050 1/20 0.51
ALDH1A1 P00352 8/20 0.49
GAA P10253 3/20 0.49
NFKB1 P19838 1/20 0.49
AGTR1 P30556 1/20 0.49
HTT P42858 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
KDM4E B2RXH2 5/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MGAM O43451 1/20 0.47
MAPT P10636 1/20 0.47
SI P14410 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL171893 0.83 KDM4E (0.62) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL3635025 0.82 KDM4E (0.60) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL648507 0.82 MAPT (0.60) SMN1; SMN2HPGDL3MBTL1ALDH1A1GAA
SCHEMBL9618481 0.82 SCN3A (0.60) SMN1; SMN2HPGDL3MBTL1TP53ALDH1A1
SCHEMBL15011086 0.79 SMN1; SMN2 (0.66) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL17186325 0.77 KDM4E (0.60) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
Hydrochloric Acid SCHEMBL17186457 0.76 KDM4E (0.59) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1
SCHEMBL2688165 0.76 KDM4E (0.55) SMN1; SMN2HPGDL3MBTL1ALDH1A1GAA
SCHEMBL30855028 0.75 SMN1; SMN2 (0.51) SMN1; SMN2HPGDL3MBTL1ALOX15ALDH1A1
SCHEMBL11311373 0.75 NPC1 (0.61) SMN1; SMN2HPGDNPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US disclosed
EP-1912959-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-23 EP disclosed
WO-2007016228-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors BMX, CDK1, CKS1B SMN1; SMN2 1919/4885HPGD 4343/4885NPC1 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.